Thursday, May 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

The Alarming Truth About Health Insurance Denials

Summary

In this episode of the Daily Remedy Podcast, the host discusses the alarming rates of health insurance claim denials, particularly under the Affordable Care Act. With statistics showing that one in five claims are denied, the conversation delves into the reasons behind these denials, including socioeconomic factors and the business model of insurance companies. The host argues that the high denial rates reflect a systemic issue within the industry, raising questions about consumer protection and potential fraud.

Takeaways

  • One out of every five claims made through ACA were denied.
  • UnitedHealthcare has the highest denial rate at 33%.
  • Socioeconomic status significantly impacts denial rates.
  • Patients with lower incomes face higher denial rates.
  • 54% of denied claims are eventually paid out.
  • Denials are a feature, not a bug, in health insurance.
  • 4.5 million claims were denied by Blue Cross Blue Shield of Alabama.
  • The denial rates indicate a systemic issue in the industry.
  • Health insurance companies may be committing fraud.
  • Consumer protection is crucial in addressing these issues.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!